Exceptionally rapid recurrence of malignant meningioma: case report. Rapid recurrence of malignant meningioma
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The publication is free and its contents are distributed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND 4.0). The rights of the works published in this journal are property of the author and they are free to distribute and disseminate the same sources as long as he correctly cites the font of publication, these acts are not for commercial purposes and no derivative works are generated.
Main Article Content
Abstract
Anaplastic meningioma represents less than 5% of all meningiomas. It is a neoplasm with a poor prognosis due to aggressiveness and a high rate of recurrence. Patients could remain asymptomatic but clinical characteristics of mass effect are the most common presentation. Although diagnosis is made with histological study, this method is difficult to define, with inter-observer variability. When possible, surgical resection is the primary management. We discuss a case of an adult female patient with tonic-clonic seizures and weakness attributed to an anaplastic meningioma in the occipital lobe. The patient was treated with a parietal craniotomy with complete resection. One month later the patient suffered a recurrence of the tumor with the need for further intervention with incomplete resection. Due to extent of the damage the patient deceased two weeks later.
References
Backer-Grøndahl, T., Moen, B. H., & Torp, S. H. (2012). The histopathological spectrum of human meningiomas. Int J Clin Exp Pathol, 5(3), 231-242.
Boulagnon-Rombi, C., Fleury, C., Fichel, C., Lefour, S., Marchal Bressenot, A., & Gauchotte, G. (2017). Immunohistochemical Approach to the Differential Diagnosis of Meningiomas and Their Mimics. J Neuropathol Exp Neurol, 76(4), 289-298. https://doi.org/10.1093/jnen/nlx008
Chamberlain, M. C., Glantz, M. J., & Fadul, C. E. (2007). Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology, 69(10), 969-973. https://doi.org/10.1212/01.wnl.0000271382.62776.b7
Combs, S. E., Hartmann, C., Nikoghosyan, A., Jäkel, O., Karger, C. P., Haberer, T., . . . Schulz-Ertner, D. (2010). Carbon ion radiation therapy for high-risk meningiomas. Radiother Oncol, 95(1), 54-59. https://doi.org/10.1016/j.radonc.2009.12.029
Darlix, A., Zouaoui, S., Rigau, V., Bessaoud, F., Figarella-Branger, D., Mathieu-Daude, H., . . . Bauchet, L. (2017). Epidemiology for primary brain tumors: a nationwide population-based study. J Neurooncol, 131(3), 525-546.
https://doi.org/10.1007/s11060-016-2318-3
Dobran, M., Marini, A., Splavski, B., Rotim, K., Liverotti, V., Nasi, D., & Iacoangeli, M. (2020). Surgical Treatment and Predictive Factors for Atypical Meningiomas: A Multicentric Experience. World Neurosurg, 144, e1-e8. https://doi.org/10.1016/j.wneu.2020.03.201
Hanft, S., Canoll, P., & Bruce, J. N. (2010). A review of malignant meningiomas: diagnosis, characteristics, and treatment. J Neurooncol, 99(3), 433-443. https://doi.org/10.1007/s11060-010-0348-9
Jääskeläinen, J., Haltia, M., Laasonen, E., Wahlström, T., & Valtonen, S. (1985). The growth rate of intracranial meningiomas and its relation to histology. An analysis of 43 patients. Surg Neurol, 24(2), 165-172.
https://doi.org/10.1016/0090-3019(85)90180-6
Kaba, S. E., DeMonte, F., Bruner, J. M., Kyritsis, A. P., Jaeckle, K. A., Levin, V., & Yung, W. K. (1997). The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery, 40(2), 271-275. https://doi.org/10.1097/00006123-199702000-00007
Kallio, M., Sankila, R., Hakulinen, T., & Jääskeläinen, J. (1992). Factors affecting operative and excess long-term mortality in 935 patients with intracranial meningioma. Neurosurgery, 31(1), 2-12. https://doi.org/10.1227/00006123-199207000-00002
Karsy, M., Guan, J., Cohen, A., Colman, H., & Jensen, R. L. (2016). Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons. Neurosurg Clin N Am, 27(2), 249-260. https://doi.org/10.1016/j.nec.2015.11.002
Kaur, G., Sayegh, E. T., Larson, A., Bloch, O., Madden, M., Sun, M. Z., . . . Parsa, A. T. (2014). Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review. Neuro Oncol, 16(5), 628-636. https://doi.org/10.1093/neuonc/nou025
Kawahara, Yosuke, Nakada, Mitsutoshi, Hayashi, Yutaka, Kai, Yutaka, Hayashi, Yasuhiko, Uchiyama, Naoyuki, . . . Hamada, Jun-ichiro. (2012). Prediction of high-grade meningioma by preoperative MRI assessment. Journal of Neuro-Oncology, 108(1), 147-152. https://doi.org/10.1007/s11060-012-0809-4
Kim, D., Niemierko, A., Hwang, W. L., Stemmer-Rachamimov, A. O., Curry, W. T., Barker, F. G., . . .
Shih, H. A. (2018). Histopathological prognostic factors of recurrence following definitive therapy for atypical and malignant meningiomas. J Neurosurg, 128(4), 1123-1132. https://doi.org/10.3171/2016.11.JNS16913
Kunimatsu, A., Kunimatsu, N., Kamiya, K., Katsura, M., Mori, H., & Ohtomo, K. (2016). Variants of meningiomas: a review of imaging findings and clinical features. Jpn J Radiol, 34(7), 459-469. https://doi.org/10.1007/s11604-016-0550-6
Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., . . . Ellison, D. W. (2021). The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol, 23(8), 1231-1251. https://doi.org/10.1093/neuonc/noab106
Orton, A., Frandsen, J., Jensen, R., Shrieve, D. C., & Suneja, G. (2018). Anaplastic meningioma: an analysis of the National Cancer Database from 2004 to 2012. J Neurosurg, 128(6), 1684-1689. https://doi.org/10.3171/2017.2.JNS162282
Simpson, D. (1957). The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry, 20(1), 22-39. https://doi.org/10.1136/jnnp.20.1.22
Stafford, S. L., Perry, A., Suman, V. J., Meyer, F. B., Scheithauer, B. W., Lohse, C. M., & Shaw, E. G. (1998). Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc, 73(10), 936-942. https://doi.org/10.4065/73.10.936
Wen, P. Y., Yung, W. K., Lamborn, K. R., Norden, A. D., Cloughesy, T. F., Abrey, L. E., . . . Prados, M. D. (2009). Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol, 11(6), 853-860. https://doi.org/10.1215/15228517-2009-010
Wiemels, J., Wrensch, M., & Claus, E. B. (2010). Epidemiology and etiology of meningioma. J Neurooncol, 99(3), 307-314. https://doi.org/10.1007/s11060-010-0386-3
Willis, J., Smith, C., Ironside, J. W., Erridge, S., Whittle, I. R., & Everington, D. (2005). The accuracy of meningioma grading: a 10-year retrospective audit. Neuropathol Appl Neurobiol, 31(2), 141-149. https://doi.org/10.1111/j.1365-2990.2004.00621.x
Wilson, T. A., Huang, L., Ramanathan, D., Lopez-Gonzalez, M., Pillai, P., De Los Reyes, K., . . . Boling, W. (2020). Review of Atypical and Anaplastic Meningiomas: Classification, Molecular Biology, and Management. Front Oncol, 10, 565582. https://doi.org/10.3389/fonc.2020.565582